Maravai LifeSciences Holdings, Inc. (MRVI) Stock Forecast
Data as of Oct 31, 2026Healthcare · Current price $7.82 (-7.57%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Dec 15, 2025 | Brandon Couillard | Wells Fargo | $4.50 | -42.5% |
| May 9, 2024 | Catherine Schulte | Robert W. Baird | $10.00 | +27.9% |
Top Analysts Covering MRVI
MRVI vs Sector & Market
| Metric | MRVI | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.33 | 2.25 | 2.41 |
| Analyst Count | 3 | 8 | 19 |
| Target Upside | -10.5% | +153002.0% | +21.5% |
| P/E Ratio | -3.95 | 3.47 | 38.49 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $50M | $53M | $54M | 5 |
| 2027-03-31 | $54M | $56M | $57M | 3 |
| 2027-06-30 | $54M | $56M | $58M | 3 |
| 2027-09-30 | $50M | $52M | $53M | 3 |
| 2027-12-31 | $55M | $57M | $59M | 3 |
| 2028-12-31 | $236M | $236M | $236M | 4 |
| 2029-12-31 | $244M | $247M | $251M | 3 |
| 2030-12-31 | $260M | $263M | $267M | 3 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $-0.04 | $-0.04 | $-0.03 | 1 |
| 2027-03-31 | $-0.04 | $-0.04 | $-0.03 | 1 |
| 2027-06-30 | $-0.04 | $-0.04 | $-0.04 | 1 |
| 2027-09-30 | $-0.04 | $-0.04 | $-0.04 | 1 |
| 2027-12-31 | $-0.04 | $-0.04 | $-0.04 | 1 |
| 2028-12-31 | $-0.11 | $-0.11 | $-0.11 | 1 |
| 2029-12-31 | $-0.17 | $-0.17 | $-0.16 | 1 |
| 2030-12-31 | $-0.15 | $-0.15 | $-0.15 | 1 |
Frequently Asked Questions
What is the analyst consensus for MRVI?
The consensus among 3 analysts covering Maravai LifeSciences Holdings, Inc. (MRVI) is Buy with an average price target of $7.00.
What is the highest price target for MRVI?
The highest price target for MRVI is $10.00, set by Catherine Schulte at Robert W. Baird on 2024-05-09.
What is the lowest price target for MRVI?
The lowest price target for MRVI is $4.50, set by Brandon Couillard at Wells Fargo on 2025-12-15.
How many analysts cover MRVI?
3 analysts have issued ratings for Maravai LifeSciences Holdings, Inc. in the past 12 months.
Is MRVI a buy or sell right now?
Based on 3 analyst ratings, MRVI has a consensus rating of Buy (2.33/5) with a -10.5% upside to the consensus target of $7.00.
What are the earnings estimates for MRVI?
Analysts estimate MRVI will report EPS of $-0.04 for the period ending 2026-12-31, with revenue estimated at $53M.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.